Steven Perrin

Steven Perrin's Title

Steven Perrin currently holds the prestigious position of President and Chief Scientific Officer. His leadership and scientific acumen drive the strategic direction and research initiatives of the organization, ensuring that the company's projects align with cutting-edge scientific advancements and industry standards.

Steven Perrin's Company

Steven Perrin was the Founder and Chief Executive Officer of Anelixis Therapeutics, Inc., a company focused on developing innovative therapies. Under his guidance, Anelixis Therapeutics made significant strides in drug development, particularly in the realm of neurodegenerative diseases. His entrepreneurial spirit and scientific expertise were instrumental in the company's growth and success.

Steven Perrin's Experience

With over 20 years of drug development experience, Steven Perrin has held pivotal R&D positions at prominent organizations such as the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, Inc., and Biogen Idec, Inc. His extensive experience in these roles has equipped him with a deep understanding of the pharmaceutical industry's complexities and challenges, enhancing his ability to lead innovative research initiatives.

Steven Perrin's Achievements

One of Steven Perrin's notable achievements is his collaboration with the ALS Therapy Development Institute, where he was instrumental in developing the world's largest ALS drug development program. This groundbreaking initiative has had a significant impact on ALS research and treatment, showcasing his dedication to advancing medical science and improving patient outcomes.

Steven Perrin's Education and Expertise

Steven Perrin earned a Ph.D. in Biochemistry from Boston University Medical Center, where he also began his career as an Associate Professor of Medicine. He holds a Bachelor of Science degree from Boston College. His strong academic background and expertise in biochemistry have been fundamental to his success in the field of drug development, allowing him to contribute significantly to the scientific community.